Due to the importance of the positive feedback loop in endocrine resistance, this study provides a clinically applicable strategy consisting of STING agonists combined with AKT inhibitors to improve current antitumor therapy for endocrine‐resistant breast cancer patients. The gene discussed is STING1; the disease is breast carcinoma.